Riluzole
- Generic Name
- Riluzole
- Brand Names
- Exservan, Rilutek, Tiglutik, Riluzole Zentiva
- Drug Type
- Small Molecule
- Chemical Formula
- C8H5F3N2OS
- CAS Number
- 1744-22-5
- Unique Ingredient Identifier
- 7LJ087RS6F
- Background
A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis. Riluzole is marketed as Rilutek by Sanofi.
- Indication
For the treatment of amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease)
- Associated Conditions
- Amyotrophic Lateral Sclerosis (ALS)
- Associated Therapies
- -
Clinical Trial With Riluzole in Spinocerebellar Ataxia Type 2 (ATRIL)
- First Posted Date
- 2017-11-20
- Last Posted Date
- 2021-06-21
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 42
- Registration Number
- NCT03347344
- Locations
- 🇫🇷
Durr, Paris, France
Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS)
- First Posted Date
- 2017-09-06
- Last Posted Date
- 2019-03-27
- Lead Sponsor
- Isfahan University of Medical Sciences
- Target Recruit Count
- 20
- Registration Number
- NCT03272802
- Locations
- 🇮🇷
EMG Department, Alzahra Hospital, Isfahan, Iran, Islamic Republic of
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
- Conditions
- Interventions
- First Posted Date
- 2017-04-25
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- AB Science
- Target Recruit Count
- 495
- Registration Number
- NCT03127267
- Locations
- 🇺🇸
Johns Hopkins Medicine Brain Science Institute, Baltimore, Maryland, United States
🇧🇪University Hospital Leuven (UZ Leuven), Leuven, Belgium
🇺🇦Communal Non-Profit Enterprise of Lviv Regional Council, Lviv Regional Clinical Hospital, Neurological Department, Lviv, Ukraine
MIROCALS: Modifying Immune Response and OutComes in ALS
- Conditions
- Interventions
- First Posted Date
- 2017-02-01
- Last Posted Date
- 2022-04-11
- Lead Sponsor
- Centre Hospitalier Universitaire de Nīmes
- Target Recruit Count
- 304
- Registration Number
- NCT03039673
- Locations
- 🇫🇷
CHRU de Lille - Hôpital Roger Salengro, Lille, France
🇫🇷CHU de Limoges - Hôpital Dupuytren, Limoges, France
🇫🇷HCL - Hôpital Neurologique P. Wertheimer, Lyon, France
Riluzole in the Treatment of Spasticity in the Traumatic Chronic Spinal Cord Injury Condition
- Conditions
- Interventions
- First Posted Date
- 2016-08-09
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Assistance Publique Hopitaux De Marseille
- Target Recruit Count
- 90
- Registration Number
- NCT02859792
- Locations
- 🇫🇷
Assistance Publique Hopitaux de Marseille, Marseille, France
Effects of Riluzole on CNS Glutamate and Fatigue in Breast Cancer Survivors With High Inflammation
- First Posted Date
- 2016-06-13
- Last Posted Date
- 2021-04-14
- Lead Sponsor
- Emory University
- Target Recruit Count
- 30
- Registration Number
- NCT02796755
- Locations
- 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States
Acetylcholine Receptors From Human Muscles as Pharmacological Target for ALS
- Conditions
- Interventions
- First Posted Date
- 2016-01-01
- Last Posted Date
- 2016-01-05
- Lead Sponsor
- University of Roma La Sapienza
- Target Recruit Count
- 50
- Registration Number
- NCT02645461
Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)
- Conditions
- Interventions
- First Posted Date
- 2015-10-28
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- AB Science
- Target Recruit Count
- 394
- Registration Number
- NCT02588677
- Locations
- 🇪🇸
Hospital Carlos III, Madrid, Spain
Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)
- Conditions
- Interventions
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2021-11-05
- Lead Sponsor
- MediciNova
- Target Recruit Count
- 70
- Registration Number
- NCT02238626
- Locations
- 🇺🇸
Carolinas Healthcare System, Dept. of Neurology, Charlotte, North Carolina, United States
Safety Study of Riluzole to Treat Post-traumatic Stress Disorder (PTSD)
- First Posted Date
- 2014-06-04
- Last Posted Date
- 2021-05-24
- Target Recruit Count
- 75
- Registration Number
- NCT02155829
- Locations
- 🇺🇸
Walter Reed National Military Medical Center, Bethesda, Maryland, United States
🇺🇸Syracuse VA Medical Center, Center for Integrated Healthcare (116C), Syracuse, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.